Combination of Balsamin and Flavonoids Induce Apoptotic Effects in Liver and Breast Cancer Cells

Parminder K. Ajji¹, Ken Walder² and Munish Puri¹,3*

¹ Centre for Chemistry and Biotechnology, Deakin University, Geelong, VIC, Australia, ² Centre for Molecular and Medical Research, School of Medicine, Deakin University, Geelong, VIC, Australia, ³ Centre for Marine Bioproducts Development, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia

Flavonoids such as naringenin, quercetin, and naringin are known to exhibit anticancer properties. In this study, we examined the effects of these flavonoids on cell viability and apoptotic pathways of cancer cells, either singly or in combination with the type 1 ribosome inactivating protein, Balsamin. Treatment with flavonoids (naringenin, quercetin, and naringin) plus Balsamin for 48 h reduced HepG2 and MCF-7 cell viability, increased the activation of caspase-3 and -8, and induced apoptosis through up-regulation of pro-apoptotic genes and down-regulation of anti-apoptotic genes. Out of the three flavonoids tested, the Balsamin-Naringenin and Balsamin-Quercetin combinations appeared to be most effective compared to the Balsamin-Naringin combination. Balsamin combined with flavonoids also activated endoplasmic reticulum (ER)-stress–mediated apoptosis in breast cancer (MCF-7) cells, which was not activated by Balsamin treatment alone. These experimental results showed that Balsamin combined with flavonoids can reduce HepG2 and MCF-7 cells viability and induce apoptosis, which could be considered as a promising therapeutic approach to sensitize cells to Balsamin treatment, thereby improving its efficacy in breast or liver cancer therapy.

Keywords: bioactives, naringin, naringenin, quercetin, therapeutics, ribosome inactivating proteins

INTRODUCTION

Flavonoids are group of polyphenolic compounds found in fruits, vegetables, herbs, cereals, and dairy products (Cook and Samman, 1996). Flavonoids as a complementary medicine have attracted the attention of researchers due to their diverse pharmacological properties, including antioxidant, antibacterial, antiviral, antitumor, anti-atherosclerosis, anti-diabetic, anti-inflammatory, antithrombogenic, hypolipidemic, and neuroprotective effects (Huang et al., 2016). Such biological diversity of flavonoids appears to be associated with their ability to regulate a number of cell signaling cascades, and could play a pivotal role in human health (Williams et al., 2004).

Of all the polyphenols known, naringenin (Nar) and its derivatives are known to possess strong antioxidant potential along with other biologically beneficial effects (Salehi et al., 2019). Nar is a flavone, a type of flavonoid that is abundantly found in citrus fruits (Puri et al., 2011). It is derived from the hydrolysis of the glycone form of flavanones, such as naringin (Figure 1) (Erlund, 2004). Naringin (Nir) is a flavanone glycoside found in grapes and citrus fruits. It consists of two sugar
units (glucose and rhamnose) attached to its aglycon portion, Nar, at the 7-carbon atom (Figure 1) (Puri et al., 2012; Alam et al., 2014). Studies have shown that both Nar and Nir exert a variety of common pharmacological effects including antioxidant, anti-inflammatory, anticarcinogenic, and hepatoprotective effects (Bharti et al., 2014). Quercetin (Qu) is a flavonol, another type of flavonoid that is abundantly found in edible fruits and vegetables, and has also gained attention in human health. It consists of two aromatic rings connected via an oxygen containing heterocyclic ring (Figure 1) (Gibellini et al., 2011). Qu has reported health benefits similar to Nar and Nir, and it has also been used therapeutically in allergic conditions (such as asthma, hayfever, eczema and hives), arthritis, metabolic syndrome and mood disorders (Kelly, 2011).

Several studies have demonstrated that these flavonoids exhibit anticancer properties toward various cancers, including liver, breast, lung, colon, and bladder cancer (Park and M Pezzuto, 2012; Sharma et al., 2017). Nar inhibited the proliferation of breast cancer (MCF-7) cells by blocking insulin stimulated glucose uptake in GLUT4 (insulin responsive glucose transporter) expressing, insulin responsive MCF-7 cells. Nar blocked glucose uptake by impairing the activation of phosphoinositide3-kinase (PI3K), a key regulator of insulin induced GLUT4 translocation, and inhibiting the phosphorylation of p44/p42 mitogen-activated protein kinase (MAPK), a step essential for the insulin signaling pathway (Harmon and Patel, 2004). Nir induced apoptosis in breast cancer cells (MDA-MB-231 and BT549) by increasing the expression of pro-apoptotic markers involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad, and p53), death receptor mediated (caspase-3 and -8) and endoplasmic reticulum (ER)-stress–mediated (GRP78 and CHOP) apoptotic pathways, with no effect observed in the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, Bal increased the expression of pro-apoptotic markers and also simultaneously decreased the expression of anti-apoptotic genes, triggering apoptosis.

Balsamin (Bal), a type I ribosome inactivating protein (RIP) from Momordica balsamina, exhibits potent anti-HIV activity (Puri et al., 2012). It blocks the replication of HIV by inhibiting the translation step, occurring prior to viral budding and release (Kaur et al., 2013). Our recent studies have shown that Bal exhibits DNase-like activity, and broad spectrum antimicrobial and antioxidant activity (Ajji et al., 2016). Further, in subsequent studies on the anti-proliferative effect of Bal on liver (HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells, we showed that Bal induced apoptosis in liver cancer cells via increasing the expression of pro-apoptotic markers involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad, and p53), death receptor mediated (caspase-3 and -8) and endoplasmic reticulum (ER)-stress–mediated (GRP78 and CHOP) apoptotic pathways, with no effect observed in the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, Bal increased the expression of pro-apoptotic markers and also simultaneously decreased the expression of anti-apoptotic genes, triggering apoptosis.

Balsamin (Bal), a type I ribosome inactivating protein (RIP) from Momordica balsamina, exhibits potent anti-HIV activity (Puri et al., 2012). It blocks the replication of HIV by inhibiting the translation step, occurring prior to viral budding and release (Kaur et al., 2013). Our recent studies have shown that Bal exhibits DNase-like activity, and broad spectrum antimicrobial and antioxidant activity (Ajji et al., 2016). Further, in subsequent studies on the anti-proliferative effect of Bal on liver (HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells, we showed that Bal induced apoptosis in liver cancer cells via increasing the expression of pro-apoptotic markers involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad, and p53), death receptor mediated (caspase-3 and -8) and endoplasmic reticulum (ER)-stress–mediated (GRP78 and CHOP) apoptotic pathways, with no effect observed in the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, Bal increased the expression of pro-apoptotic markers and also simultaneously decreased the expression of anti-apoptotic genes, triggering apoptosis.

Balsamin (Bal), a type I ribosome inactivating protein (RIP) from Momordica balsamina, exhibits potent anti-HIV activity (Puri et al., 2012). It blocks the replication of HIV by inhibiting the translation step, occurring prior to viral budding and release (Kaur et al., 2013). Our recent studies have shown that Bal exhibits DNase-like activity, and broad spectrum antimicrobial and antioxidant activity (Ajji et al., 2016). Further, in subsequent studies on the anti-proliferative effect of Bal on liver (HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells, we showed that Bal induced apoptosis in liver cancer cells via increasing the expression of pro-apoptotic markers involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad, and p53), death receptor mediated (caspase-3 and -8) and endoplasmic reticulum (ER)-stress–mediated (GRP78 and CHOP) apoptotic pathways, with no effect observed in the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, Bal increased the expression of pro-apoptotic markers and also simultaneously decreased the expression of anti-apoptotic genes, triggering apoptosis.

Balsamin (Bal), a type I ribosome inactivating protein (RIP) from Momordica balsamina, exhibits potent anti-HIV activity (Puri et al., 2012). It blocks the replication of HIV by inhibiting the translation step, occurring prior to viral budding and release (Kaur et al., 2013). Our recent studies have shown that Bal exhibits DNase-like activity, and broad spectrum antimicrobial and antioxidant activity (Ajji et al., 2016). Further, in subsequent studies on the anti-proliferative effect of Bal on liver (HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells, we showed that Bal induced apoptosis in liver cancer cells via increasing the expression of pro-apoptotic markers involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad, and p53), death receptor mediated (caspase-3 and -8) and endoplasmic reticulum (ER)-stress–mediated (GRP78 and CHOP) apoptotic pathways, with no effect observed in the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, Bal increased the expression of pro-apoptotic markers and also simultaneously decreased the expression of anti-apoptotic genes, triggering apoptosis.

Balsamin (Bal), a type I ribosome inactivating protein (RIP) from Momordica balsamina, exhibits potent anti-HIV activity (Puri et al., 2012). It blocks the replication of HIV by inhibiting the translation step, occurring prior to viral budding and release (Kaur et al., 2013). Our recent studies have shown that Bal exhibits DNase-like activity, and broad spectrum antimicrobial and antioxidant activity (Ajji et al., 2016). Further, in subsequent studies on the anti-proliferative effect of Bal on liver (HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells, we showed that Bal induced apoptosis in liver cancer cells via increasing the expression of pro-apoptotic markers involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad, and p53), death receptor mediated (caspase-3 and -8) and endoplasmic reticulum (ER)-stress–mediated (GRP78 and CHOP) apoptotic pathways, with no effect observed in the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, Bal increased the expression of pro-apoptotic markers and also simultaneously decreased the expression of anti-apoptotic genes, triggering apoptosis.

FIGURE 1 | Structure of naringin and its hydrolysed product naringenin (A), and quercetin (B).
mitochondrial mediated and death receptor mediated apoptosis. Interestingly, Bal did not activate the ER-stress-mediated pathway in breast cancer cells, suggesting diverse mechanisms of apoptosis induction in different cancer cells (Ajji et al., 2017).

Bal and flavonoids (Nar, Nir, and Qu) appear to exert antitumor effects and induce apoptosis through similar mechanisms in liver (HepG2) and breast (MCF-7) cancer cells, therefore, we hypothesized that Bal-flavonoid (Nar, Nir, and Qu) combinations might have additive apoptotic effects on these cells. Thus, in this study, we examined the effect of co-treatment of Bal and three flavonoids, namely Nar, Nir, and Qu, on HepG2 and MCF-7 cells.

MATERIALS AND METHODS

Chemicals, Reagents, and Kits
Nar (purity ≥ 95%), Nir (purity ≥ 95%), and Qu (purity ≥ 95%), trypsin, in vitro toxicity assay kit, Caspase-3 assay kit and Caspase-8 assay kit were procured from Sigma-Aldrich (USA). RPMI and DMEM media, and FBS were purchased from Life Technologies Corporation (California, USA). Total RNA isolation kit was purchased from Qiagen (Hilden, Germany). CM Sepharose and Superdex 75 for Balsamin purification were procured from GE Healthcare (Buckinghamshire, UK). Reagents used for electrophoresis were purchased from Bio Rad Laboratories (California, USA). All other reagents were purchased from Sigma-Aldrich (USA) and were of analytical grade.

Purification of Balsamin
Balsamin was purified from Momordica balsamina seeds based on our earlier published method (Kaur et al., 2012). The seeds were powdered and homogenized in 50 ml of 150 mM NaCl. The slurry obtained was centrifuged at 12,000 g for 20 min at 4°C. Following centrifugation, the proteins were precipitated from the supernatant with the addition of ammonium sulphate. The precipitate obtained after centrifugation was dissolved in 10 mM phosphate buffer (PB), pH 6.5, and dialysed against the same buffer. Following equilibration of a CM-Sepharose column with PB, pH 6.5, the dialysed sample was loaded onto the column and elution of unbound protein was carried out with PB, pH 6.5. The bound proteins were eluted with 0.1–0.4 M NaCl in PB, pH 6.5. The peak fractions containing the protein of interest (analyzed by SDS-PAGE) were pooled, concentrated and loaded onto a Superdex 75 column equilibrated with PB, pH 6.5. The eluted fractions with the desired protein were pooled, concentrated, and further used for this study. The purified Bal was characterized by SDS-PAGE and protein concentration was determined by the Bradford method (Kaur et al., 2012).

Cell Lines and Cell Culture
Liver (HepG2) and breast (MCF-7) cancer cells lines were investigated. These cell lines were procured from the American Type Culture Collection (Rockville, MD, US). HepG2 and MCF-7 cells were maintained in RPMI and DMEM media supplemented with heat inactivated 10% FBS, respectively, in an environment of 5% CO₂ at 37°C. These cells were proliferated in T-25 flasks until 80% confluence and split 1:10 and 1:4, separately, in culture dishes before experiments were performed.

Treatment Groups
For the cell viability assay, the treatment regimes given in Figure 2 were used. Based on empirical data, treatments highlighted in Figure 2 were selected for all other assays.

Cell Viability Assay
HepG2 and MCF-7 cells were seeded in 96 well plates in a seeding density of ~1 × 10⁴ cells/well for 24 h. After incubation, the cells were exposed to the treatment regimes given in Figure 2 for 24 h. Cell viability was then analyzed using an in vitro toxicology assay kit. MTT reagent was added to each well and the cells were incubated for 4 h. The MIT formazone dye crystals formed during the experiment were dissolved in MTT solubilization solution and the absorbance was measured using a microplate reader (Bio-Rad, USA) at a wavelength of 570 nm. All experiments were performed three times and results were expressed as mean ± standard deviation.

Morphology Assay
Hep G2 and MCF-7 cells were seeded in 6-well plates in a seeding density of (~1 × 10⁵ cells/well) for 24 h. After 24 h, the cells were treated with the treatments highlighted in Figure 2 for 48 h. Cell morphology was then examined using a light microscope.

Caspase-3/-8 Activity Assay
HepG2 and MCF-7 cells were seeded in 24 well plates in a seeding density of 6 × 10⁴ cells/well) for 24 h. After 24 h, the cells were treated with treatments highlighted in Figure 2 for 48 h. After collecting and lysing the cells; caspase-3 and caspase-8 activity was determined immediately. The activity of caspase-3 and caspase-8 in triplicate was determined using caspase-3 and caspase-8 colorimetric assay kits according to the manufacturer's protocol. Briefly, 5 µl of cell lysate and 1X assay buffer were added to the 96-well plate followed by caspase-3 substrate (AcDEVD-pNA) and caspase-8 substrate (AcIETD-pNA) to each well, respectively. The plates were incubated at 37°C for 2 h. Finally, the absorbance of pNA catalyzed by caspase-3 and caspase-8, respectively were measured using microplate system at 405 nm. All experiments were performed three times and results were expressed as mean ± standard deviation.

RNA Extraction and RT-PCR for Gene Expression Studies
HepG2 and MCF-7 cells were seeded in 24 well plates in a seeding density of 6 × 10⁴ cells/well for 24 h. After incubation, the cells were treated with the treatments highlighted in Figure 2 for 48 h. After treatment, total RNA was extracted using a Total RNA isolation kit (Qiagen) according to the protocol described by the manufacturer.

Maxima H minus first strand cDNA synthesis kit was used to synthesize first strand complementary DNA (cDNA) from each
RNA sample. RT-PCR was carried out at 50°C for 30 min, followed by 85°C for 5 min and 4°C for 5 min, using the following primers sets: Bid: 5'-GCT GTA TAG CTG TA -3' (forward), 5'-GCT ATC TTC CAG CCT GTC TTC TC -3' (reverse); p53: 5'-CTG TCA TCT TCT GTCT CTT TC -3' (forward), 5'-TGG GAT AAT CAC ACA GCT GCA -3' (forward); Bax: 5'-CTG CAG AGG ATG ATT GCC G -3' (forward), 5'-TGG AAT CAA CCC ACA GTT GCA -3' (forward); Bad: 5'-GCA CAG CAA CGC AGA TGC -3' (forward), 5'-AAG TTC CGA TCC CAC CAG G -3' (reverse); Bcl2: 5'-CTG TGG AGA GGC TCA ACC G -3' (forward), 5'-CCT CTG TTT GAT TTC TCC TGG CT -3' (reverse); Bcl-XL: 5'-GAT CCC CAT GGC AGC AGT AAA GCA AG -3' (forward), 5'-CCC CAT CCC GGA AGA GTT CAT TCA CT -3' (reverse); GRP78: 5'-GGT GAC CTG GTA CTG TTT GAT G -3' (forward), 5'-CCT TGG AAT CAG TTT GGT CAT G -3' (reverse); CHOP: 5'-TGC TTC TCT GGC TTG GCT GAC -3' (forward), 5'-CCA AGG GAG AAC CAG GAA ACG G -3' (reverse) (see Table 1).

PCR was carried out in a reaction mixture of 10 µl under following conditions: 95°C for 7 min, 40 cycles at 95°C for 30 s and 60°C for 1 min, 60°C for 60 s, 55°C–95°C (hold time: 1 s, temperature increment after hold: 0.2°C), and 20°C for 10 s. All experiments were performed three times and results were expressed as mean ± standard deviation.
Statistical Analysis
Data was analyzed using SPSS Statistics software version 22.0. Data was presented as the mean ± SD for at least three independently performed experiments unless otherwise stated. The non-parametric test, Kruskal-Wallis H test, also known as one-way ANOVA on ranks, was used to compare the difference between two or more groups. Mann-Whitney U test was used to compare the difference between two groups. Probability values with p < 0.05 were considered to be statistically significant.

RESULTS

Growth Inhibitory Effects of Bal Combined With Flavonoids on Hepg2 and MCF-7 Cells
We first determined the effect of co-treatment of Bal (25 µg/ml) and flavonoids (Nar, Nir, or Qu) on the viability of HepG2 and MCF-7 cells using an in vitro toxicology assay kit. As shown in Figures 3A, B, the combination of Bal with low dose (0.5 × IC₅₀ dose) of Nar appeared to inhibit the viability of HepG2 and MCF-7 cells compared to the cells treated with Bal and Nar alone. However, when the concentration of Nar (1.0 × IC₅₀ and 2.0 × IC₅₀) was increased in combination with Bal, no significant difference between the Bal-Nar and Nar treated groups was observed, suggesting that 0.5 × IC₅₀ of Nar with Bal could be the most effective dose combination (Figures 3A, B).

Further, the trend appeared to be similar when HepG2 and MCF-7 cells were treated with Bal-Qu combinations (Figures 4A, B). However, when HepG2 and MCF-7 cell were co-treated with low dose (0.5 × IC₅₀) of Nir and Bal, the cell viability tended to decrease slightly compared to singly treated groups, however, the effect was not as prominent as observed with low dose (0.5 × IC₅₀) of Nar or Qu with Bal. Further, when the concentration of Nir (1.0 × IC₅₀ and 2.0 × IC₅₀) was increased in combination with Bal, no significant difference was observed in the groups treated with Bal-Nir combinations and Nir alone (Figures 5A, B). These results suggest that flavonoids (Nar, Nir, and Qu) could increase the anti-proliferative effects of Bal on HepG2 and MCF-7 cells, with low dose (0.5 × IC₅₀) of flavonoids (Nar, Nir, and Qu) found to be the most effective dose in combination with Bal. Therefore, we selected this flavonoid dose in combination with Bal for further study.

Effect of Bal-Flavonoid Combination on the Morphology of HepG2 and MCF-7 Cells
We next investigated if flavonoids (Nar, Nir, or Qu) could increase Bal induced apoptotic effects in HepG2 and MCF7 cells. For this, we examined the morphology of HepG2 and MCF-7 cells treated with combinations of Bal and Nar, Nir, or Qu, and compounds alone under bright field microscopy. The results showed that apoptotic morphological changes, such as loss in cell connections, cell shrinkage, cell surface detachment, increased cytoplasmic density and more dead cells appeared to be more prominent in cells treated with Bal-flavonoid (Nar, Nir, or Qu) combinations compared to single treatments (Figure 6).

Caspase-3 and -8 Activity of Bal Combined With Nar, Nir, or Qu in HepG2 and MCF-7 Cells
We further decided to evaluate whether flavonoids (Nar, Nir, and Qu) increase caspase-mediated apoptotic effects in Bal treated HepG2 and MCF-7 cells. As shown in Figure 7A, Bal-Nar treatment tended to increase and appeared to have an additive effect on caspase-3 and -8 activity in HepG2 and MCF-7 cells compared to Bal and Nar alone. Further, the trend appeared to be similar in HepG2 and MCF-7 cells treated with the Bal-Qu combination (Figure 7B). However, when HepG2 and MCF-7 cells were treated with the Bal-Nir combination, the caspase-3 and -8 activity tended to increase as compared to Nir and Bal treatment alone, however, did not appear to have an additive effect (Figure 7C).

Effect of Bal-Flavonoid Combinations on the Expression of Various Apoptotic Genes Involved in the Mitochondrial Cell Death Pathway
We next studied if these flavonoids could increase Bal-induced mitochondrial apoptotic effects in HepG2 and MCF-7 cells. The qRT-PCR results showed that Bal-Nar treatment tended to increase and appeared to have an additive effect on the expression of Bax, Bid, Bad, and p53 compared to Bal treatment alone in HepG2 and MCF-7 cells. However, no significant difference was observed between the groups (Figure 8A). Further, the trend appeared to be similar in HepG2 and MCF-7 cells treated with the Bal-Qu combination (Figure 8B).

TABLE 1 | Primers used for RT-PCR.

| Gene | Forward primer (5’-3’) | Reverse primer (5’-3’) |
|------|------------------------|-----------------------|
| Bid  | GCTGTTAGCTGCTCCTGCACTGT | GCTATCTCCAAGGCCTGTCCTCTC |
| p53  | CTTGCTACCTCTGCTGGCACTG | TGAGAATCCACCCACAAGTGCA |
| Bax  | CTGCAAGGGCTGCTGGGCACTC | TGCACTCCGAAAAAGACCTT |
| Bad  | GCAGCCAGCAAGCGAGGACQ | AAGTTCGATGAAGCGAGG |
| Bcl2 | GTGTGGAAGGCTGCTCGGCACTC | CGCCATCGGAGAACAGTTCATTCACT |
| Bcl-XL | GATGTGCAAGCAACGAAAGCAAG | CACCCATCCCGGAAGAGTTCATTCACT |
| GRP78 | GCTGACCTGGACTCCTTGATG | CCTTGGAATCAGTTTGGTCATG |
| CHOP | TGGCTTTCTGCTGGCTGAC | CGTCAAGTCGTTTGATTTCTCCTGGCT |

Aji et al. Flavonoids and Balsamin Combination Induced Apoptosis
suggesting that Nar and Qu increase Bal-induced apoptotic effect in HepG2 and MCF-7 cells.

In addition, the Bal-Nir combination appeared to increase the expression of \textit{Bax}, \textit{Bid}, \textit{Bad} and \textit{p53} as compared Bal treatment alone in HepG2 and MCF-7 cells. However, the effect did not appear to be pronounced and additive compared to Bal-Nar and Bal-Qu treatment (Figure 8C), suggesting that the Bal-Nar and Bal-Qu combinations could be considered more effective than the Bal-Nir combination.

Further, we also evaluated the expression of anti-apoptotic genes (\textit{Bcl-2} and \textit{Bcl-XL}) in HepG2 and MCF-7 cells treated with Bal-flavonoid (Nar, Nir, or Qu) combinations. The qRT-PCR results showed that Bal-Nar treatment tended to decrease the expression of \textit{Bcl-2} and \textit{Bcl-XL} compared to Bal and Nar treatment alone in HepG2 and MCF-7 cells, indicating a possible effect. However, no significant difference was observed between the groups (Figure 9A). Likewise, the trend appeared to similar, but less pronounced in HepG2 and MCF-7 cells with Bal-Qu and Bal-Nir combinations (Figures 9B, C).

**Effect of Bal-Flavonoid Treatment on the Expression of Genes Involved in Endoplasmic Reticulum-Stress–Mediated Apoptosis**

To investigate whether Bal-flavonoid treatment could increase Bal-induced ER stress in HepG2 cells and activate this pathway in breast cancer (MCF-7) cells, we evaluated the expression of \textit{CHOP} and \textit{GRP78} in Bal-flavonoid (Nar, Nir, and Qu) treated HepG2 and MCF-7 cells.

The qRT-PCR results showed that the expression of \textit{GRP78} and \textit{CHOP} tended to increase in HepG2 cells treated with Bal-Nar (Figure 10A), Bal-Qu (Figure 10B), and Bal-Nir (Figure 10C) combinations compared to Bal and flavonoids (Nar, Nir, and Qu) treatment alone, indicating a possible additive effect of

---

**FIGURE 3** | Effect of Bal and Nar on the viability of HepG2 (A) and MCF-7 (B) cells compared with Bal. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.05, Kruskal-Wallis H test.
co-treatment in HepG2 and MCF-7 cells. In the case of MCF-7 cells, Bal treatment alone did not increase the expression of GRP78 and CHOP. However, when Bal was combined with the flavonoids (Nar, Qu, and Nir), the expression tended to increase with respect to Bal alone, but did not increase significantly with respect to flavonoid (Nar, Qu, and Nir) treatment alone, suggesting that the effect was entirely due to the presence of the flavonoid (Nar, Qu, or Nir) in the Bal-flavonoid combinations (Figures 10A–C).

DISCUSSION

The relationship between diet and cancer has been implicated in number of epidemiological studies (Ross, 2010). Vegetables, fruits, and cereals contain flavonoids that have antioxidant, anti-inflammatory and anticancer properties and Nar, Nir, and Qu are three such flavonoids that have been explored for their anti-proliferative effects toward various cancer cells. Nar, a natural flavone exhibits anti-tumor activity toward various tumor cell types including hepatoma (HepG2), breast cancer (MCF-7, HTB26 and HTB132), leukemia (K562), human epidermoid carcinoma (A431), colorectal cancer (SW1116 and SW837), and glioma cells (C6) (Harmon and Patel, 2004; Sabarinathan et al., 2011; Arul and Subramanian, 2013; Ahamad et al., 2014; Abaza et al., 2015; Li et al., 2015). Nir exerts antiproliferative effects on cancer cells such as breast cancer (MDA-MB-231 and BT549), liver cancer (HepG2), bladder cancer (5637), melanoma (A375), and glioblastoma (U87MG) (Kim et al., 2008; Guo et al., 2016; Li et al., 2016). Qu possesses antitumor activity against liver cancer (HepG2), breast cancer (MCF-7), leukemia (HL-60) and prostate cancer (DU-145 and PC-3) cells (Nair et al., 2004; Niu et al., 2011; Deng et al., 2013; Zhao et al., 2014).

Nar caused cell death via cytotoxic, genotoxic and apoptosis effect on various cancer cell lines including HT-29, MCF-7 and

FIGURE 4 | Effect of Bal and Qu on the viability of HepG2 (A) and MCF-7 (B) cells compared with Bal. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.05, Kruskal-Wallis H test.
PC-12 through the production of ROS and DNA damage in a dose dependent manner. However, the effects were found to be nominal in case of normal cell line, L-929 as the IC\textsubscript{50} value of Nar for L-929 cell line could not be determined since the value was out of range (Kocyigit et al., 2016). Qu induced cytotoxicity in a dose dependent manner in leukemic (CEM and K562) and breast cancer (T47D and EAC) cells through DNA fragmentation, cell cycle arrest and activating intrinsic pathway of apoptosis. However, normal cells derived from human embryonic kidney (293T) as well as mouse embryonic fibroblast (MEF-1) were found to be insensitive to quercetin (Srivastava et al., 2016) at similar concentrations able to induce death in carcinogenic cells (different works have already published this result).

Several studies have reported that flavonoids with antioxidant properties synergize the effect of chemotherapeutic drugs (Lewandowska et al., 2014). Qu increased cisplatin-induced apoptosis in human laryngeal cancer (Hep-2) cells (Kuhar et al., 2007). 4T1 breast tumor mice treated with Qu and doxorubicin demonstrated inhibition of tumor growth and reduction of doxorubicin side effects, leading to prolonged survival of the mice (Du et al., 2010). Qu enhanced the antitumor effect of trichostatin-A, a novel anticancer drug, in human lung cancer cells through upregulation of p53 expression (Chan et al., 2013).

Our previous studies demonstrated that Bal, a type I RIP isolated from Momordica balsamina, exhibits inhibitory effects toward HIV-1 replication (Kaur et al., 2013) and breast cancer cells, highlighting its potential as a therapeutic agent. It has previously been reported that Bal-induced apoptosis involved increases in caspase-3 and caspase-8 activity, cell cycle arrest at G-/S- phase, upregulation of Bax, Bid, and Bad, and downregulation of BCL-2 and BCL-XL (Ajji et al., 2017).

Since flavonoids (Nar, Nir, and Qu) and Bal exerts anticancer effects, therefore the present study investigated the apoptotic effects of Bal in the presence of three flavonoids, namely Nar, NIR, and Qu, on liver (HepG2) and breast cancer (MCF-7) cells. Co-treatment with Bal (25 µg/ml) and flavonoids (Nar, Nir, or Qu) enhanced the anti-proliferative effects of Bal on HepG2 and

**FIGURE 5** | Effect of Bal and Nir on the viability of HepG2 (A) and MCF-7 (B) cells compared with Bal. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.05, Kruskal-Wallis H test.
FIGURE 6 | Morphology of HepG2 and MCF-7 cells treated with Bal-Nar, Bal-Qu and Bal-Nir compared with Bal, Nar, Qu and Nir alone.

FIGURE 7 | Effect of Bal-Nar (A), Bal-Qu (B) and Bal-Nir (C) on caspase-3 and -8 activity compared with Bal in HepG2 and MCF-7 cells. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.05, Kruskal-Wallis H test.
MCF-7 cells where low dose (0.5 × IC50) of flavonoids (Nar, Nir, and Qu) in combination with Bal was found to be an effective dose as compared to other two doses (1.0 × IC50 and 2.0 × IC50) of Nar, Nir, or Qu, and henceforth the lowest dose (0.5 × IC50) of Nar, Nir, and Qu was selected in combination with Bal for further study. These doses were selected based on the empirical data; however, further investigations would be required to evaluate appropriate doses of Bal and flavonoids for alleviating liver and breast cancer in clinical trials.

Flavonoids, such as Nar, Nir, and Qu are known to induce apoptosis in various cancer cells by regulating the expression of apoptotic markers (Arul and Subramanian, 2013; Banjerdpongchai et al., 2016). Apoptosis is a programmed and often energy dependent process that involves activation of caspasas, a group of cysteine proteases, and a complex cascade of signals (Elmore, 2007). Flavonoids such as Nar, Nir, and Qu have been reported to activate caspase dependent apoptosis in cancer cells (Ramos, 2007). Nar and Nir induced apoptosis in...
HepG2 cells via activating caspase-8 and caspase-9 mediated cell death pathways (Arul and Subramanian, 2013; Banjerdpongchai et al., 2016). Qu induced cell death in glioblastoma U373MG cells through proteolytic activation of caspase-3 and caspase-7, a decrease in mitochondrial membrane potential and increases in caspase-3 and caspase-9 activities (Kim et al., 2013). Our previous studies have demonstrated that Bal also induces apoptosis by increasing the activity of caspase-3 and -8 in breast cancer cells (Ajji et al., 2017). In this study, Bal in combination with flavonoids (Nar, Nir, and Qu) had an additive effect on caspase-3 and -8 activity in HepG2 and MCF-7 cells compared to Bal and flavonoids (Nar, Nir, and Qu) treatment alone. Out of three combinations, Bal-Nar and Bal-Qu appeared to have a more prominent effect compared to Bal-Nir combination. Increase in activation of caspase-3 and -8, upregulation of pro-apoptotic genes (Bax, Bid, Bad, p53) and downregulation of anti-apoptotic genes (Bcl-2 and Bcl-XL) with Bal-Nar, Bal-Nir and Bal-Qu treatment compared to Bal and flavonoid (Nar, Nir, or Qu) treatment alone in HepG2 and MCF-7 cells, suggested that these flavonoids increase Bal-induced mitochondrial mediated apoptosis with a possible additive effect in HepG2 and MCF-7 cells, which could be considered as a promising strategy to sensitize cells to Bal treatment.

The ER stress response has been reported to initiate apoptosis in various cancer cells, through three different pathways; (i) activation of CHOP, also known as DNA damage-inducible gene 153 (GADD153), (ii) activation of ER associated caspases and (iii) activation of c-Jun N-terminal kinase (JNK)-mediated cell death (G Johnson et al., 2011). Qu induced ER-stress–mediated apoptosis by increasing the expression of ATF, GRP78 and CHOP in prostate cancer PC-3 cells (Liu et al., 2014). It has been reported that Qu pre-treatment elicits ER-stress to enhance cisplatin cytotoxicity in ovarian cancer cells, indicating that Qu has a potential to enhance the efficacy of cisplatin induced apoptosis in ovarian cancer cells (Yang et al., 2015). Our studies have shown that Bal does not activate ER-stress–mediated apoptosis in breast cancer (MCF-7 and BT549) cells (Ajji et al., 2017). However, co-treatment with Bal and flavonoids (Nar, Nir, and Qu) tended to increase and appeared to have an additive effect on the expression of GRP78 and CHOP in HepG2 cells compared to Bal and flavonoids (Nar, Nir, and Qu) treatment alone. However, in case of MCF-7 cells, Bal-flavonoid (Nar, Qu, or Nir) treatment tended to increase the
expression GRP78 and CHOP with respect to Bal alone, but did not increase significantly with respect to flavonoid (Nar, Qu, and Nir) treatment alone, indicating that the effect was entirely due to the presence of the flavonoid in the combined treatment. It is interesting to note that some of these flavonoids activate ER-stress-mediated apoptosis, an additional apoptotic pathway, in breast cancer MCF-7 cells that is not activated by Bal treatment alone.

A number of studies have reported the bioavailability of flavonoids such as Nar, Qu, and Nir in rats. The plasma concentration of Nar and Qu metabolites in rats receiving single meal containing 0.25% Nar and 0.2% Qu after 24 h was found to be 128 µM and 51 µM, respectively. The plasma concentration of Nar and Qu increased till 10-12 h after single feed and decreased thereafter indicating that these flavonoids are efficiently absorbed in rats (Manach et al., 1997; Felgines et al., 2000). Our results suggested that consumption of these flavonoids (Nar, Qu, and Nir) with Bal at selected doses might be beneficial to prevent and treat liver and breast cancer, thus advocating its use as a dietary supplement. It could be a promising therapeutic strategy to sensitize liver and breast cells to Bal treatment, thereby improving its effectiveness in cancer therapy. However, further investigations would be required to evaluate appropriate doses of Bal and flavonoids for alleviating liver and breast cancer in clinical trials.

CONCLUSIONS

To the best of our knowledge, our study demonstrates for the first time that Bal in combination with flavonoids (Nar, Nir, and Qu) enhances apoptotic effects in HepG2 and MCF-7 cells through activation of caspase-3 and -8 and regulation of pro-apoptotic and anti-apoptotic genes. These results suggested that Bal with flavonoids (Nar, Qu, and Nir) could be a promising therapeutic strategy to reduce proliferation in breast and liver cancer cells and sensitize cells to Bal treatment. However, the study warrants further investigation to evaluate the efficacy and appropriate doses of Bal and flavonoids for alleviating liver and breast cancer in clinical trials.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

PA conducted experiments, analyzed data, and wrote the manuscript. KW participated in the experimental planning, analyzed the data, and edited the manuscript. MP conceived the study, planned the experiments, analyzed the data, and edited the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

Abaza, M. S. L., Orabi, K. Y., Al-Quattan, E., and Rajaa, J. (2015). Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer. Cancer Cell Int. 15 (1), 1. doi: 10.1186/s12935-015-0194-0

Ahamad, M. S., Siddiqui, S., Jafari, A., Ahmad, S., Afzal, M., and Arshad, M. (2014). Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest. PloS One 9 (10), e110003. doi: 10.1371/journal.pone.0110003

Ajji, P. K., Walder, K., and Puri, M. (2016). Functional Analysis of a Type-I Ribosome Inactivating Protein from Momordica balsamina with Anti-Microbial and DNase Activity. Plant Foods Hum. Nutr. 71 (3), 265–271. doi: 10.1007/s11130-016-0555-4

Ajji, P. K., Binder, M. J., Walder, K., and Puri, M. (2017). Balsamin induces apoptosis in breast cancer cells via DNA fragmentation and cell cycle arrest. Mol. Cell. Biochem. 432, 189–198. doi: 10.1007/s11010-017-3009-x

Ajji, P. K. (2017). Functional characterization of a novel ribosome inactivating protein from Momordica balsamina. [PhD thesis] (Victoria, Australia: Deakin University).

Alam, M. A., Subhan, N., Rahman, M. M., Uddin, S. J., Reza, H. M., and Sarker, S. D. (2014). Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv. Nutr. 5 (4), 404–417. doi: 10.3945/an.113.005603

Arul, D., and Subramanian, P. (2013). Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol. Oncol. Res. 19 (4), 763–770. doi: 10.1007/s12253-013-9641-1

Banerjee et al. (2020). Balsamin-induced apoptosis in human colorectal cancer cells. J. Pathol. Oncol. 19 (4), 763–770. doi: 10.1007/s12253-013-9641-1

Bharti, S., Rani, N., Krishnamurthy, B., and Arya, D. S. (2014). Preclinical evidence for the pharmacological actions of naringin: a review. Planta Med. 80 (06), 437–451. doi: 10.1055/s-0034-1368351

Chan, S. T., Yang, N. C., Huang, C. S., Liao, J. W., and Yeh, S. L. (2013). Quercetin enhances the antioxidant activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PloS One 8 (1), e54255. doi: 10.1371/journal.pone.0054255

Cook, N., and Samman, S. (1996). Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources. J. Nutr. Biochem. 7 (2), 66–76. doi: 10.1016/0955-2863(95)00168-9

Deng, X. H., Song, H. Y., Zhou, Y. F., Yuan, G. Y., and Zheng, F. J. (2013). Effects of quercetin on the proliferation of breast cancer cells and expression of survivin in vitro. Exp. Ther. Med. 6 (5), 1155–1158. doi: 10.3892/etm.2013.1285

Du, G., Lin, H., Wang, M., Zhang, S., Wu, X., Lu, L., et al. (2010). Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother. Pharmacol. 65 (2), 277–287. doi: 10.1007/s00280-009-1032-7

Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (4), 495–516. doi: 10.1080/0192623070120337
Erfund, I. (2004). Review of the flavonoids quercetin, hesperidin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr. Res. 24 (10), 851–874. doi: 10.1016/j.nutres.2004.07.005

Felgentreu, C., Texier, O., Morand, C., Manach, C., Scalbert, A., Regerat, F., et al. (2000). Bioavailability of the flavanone naringenin and its glycosides in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (6), 1148–1154. doi: 10.1152/ajpgi.2000.279.6.G1148

G Johnson, G., White, M., and Grimaldi, M. (2011). Stressed to death: targeting endoplasmic reticulum stress response induced apoptosis in gliomas. Curr. Pharm. Des. 17 (3), 284–292. doi: 10.2174/138161211795049660

Gibellini, L., Pinti, M., Nasi, M., Montagna, J. P., De Biasi, S., Roat, E., et al. (2011). Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J. Nutr. 136 (11), 2715–2721. doi: 10.1093/jn/136.11.2715

Guo, B., Zhang, Y., Hui, Q., Wang, H., and Tao, K. (2016). Naringin suppresses the metabolism of A375 cells by inhibiting the phosphorylation of c-Src. Tumor Biol. 37 (5), 3841–3850. doi: 10.1007/s13277-015-4235-2

Harmon, A. W., and Patel, Y. M. (2004). Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res. Treat. 85 (2), 103–110. doi: 10.1007/BF03379519

Huang, H. C., Huang, C. W., Chen, M. C., Tu, Y. H., and Wang, C. C. (2016). Chrysian, a Admirant in Morinda Citrifolia fruit water-ElOAc extracts, combined with agginen synergistically induced apoptosis and inhibited migration in human breast and liver cancer cells. J. Agric. Food Chem. 64 (21), 4235–4245. doi: 10.1021/acs.jafc.6b00766

Kaur, I., Yadav, S., Hariprasad, G., Gupta, R. C., Sinivasan, A., Batra, J., et al. (2012). Balsamin, a novel ribosome-inactivating protein from the seeds of Balsam apple Momordica balsamina. Amino Acids 43 (2), 973–981. doi: 10.1007/s00726-011-1162-1

Kaur, I., Kaur, P., Ahmed, Z., Blanchet, F. P., Mangeat, B., and Piquet, V. (2013). Inhibition of HIV-1 Replication by Balsamin, a Ribosome Inactivating Protein of Momordica balsamina. Pho One 8 (9), e73780. doi: 10.1371/journal.pone.0073780

Kelly, G. S. (2011). Quercetin. Altern. Med. Rev. 16 (2), 172–194.

Kim, D. I., Lee, S. J., Lee, S. B., Park, K., Kim, W. J., and Moon, S. K. (2008). Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and endoplasmic reticulum stress response induced apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells. Acta Biochim. Biophys. Sin. 43 (1), 30–37. doi: 10.1093/abbs/gqm017

Kaur, I., Puri, M., Ahmed, Z., Cho, K. S. (2013). Quercetin and cancer chemoprevention. Evit. Based Complement. Altern. Med. 2011, 1–15. doi: 10.1093/ecam/nep053

Kocyigit, A., Koyuncu, I., Dikilitas, M., Bahadori, F., and Turkkan, B. (2016). Naringenin suppresses the proliferation of cerebral implanted C6 glioma cells in rats. Chem. Biol. Interact. 189 (1), 26–36. doi: 10.1016/j.cbi.2010.09.028

Salehi, B., Fouko, P. V. T., Sharif-Hemadi, M., Zucca, P., Pezzani, R., Martins, N., et al. The Thermapeutic Potential of Naringenin: A Review of Clinical Trials. Pharmaceutica. (Basel) 12 (11), 1. doi: 10.3390/ph12011001

Sharma, D., Nijhwan, M., and Puri, M. (2017). “Multifunctional bioactives for cancer therapy,” in M. Puri ed. Food Bioactives: Extraction and Biotechnological Applications. Chapter 12. (Springer Press), 299–323.

Srivastava, S., Somasagar, R. R., Hegde, M., Nishana, M., Tadi, S. K., Srivastava, M., et al. (2016). Quercetin, a Natural Flavonoid Interacts with DNA, Arrests Cell Cycle and Causes Tumor Regression by Activating Mitochondrial Pathway of Apoptosis. Sci. Rep. 6, 240–249.

Williams, R. J., Spencer, J. P., and Rice-Evans, C. (2004). Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med. 36 (7), 838–849. doi: 10.1016/j.freeradbiomed.2004.01.001

Yang, Z., Liu, Y., Liao, J., Gong, C., Sun, C., Zhou, X., et al. (2015). Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of GSTA3 signaling. FEBS J. 282 (6), 1111–1125. doi: 10.1111/febs.13206

Zhao, F., Mao, J. M., Zhang, S. Y., Zhou, Z. Q., Tan, Y., and Zhang, Y. (2014). Quercetin induces HepG2 cell apoptosis by inhibiting fatty acid biosynthesis. Oncol. Lett. 8 (2), 765–769. doi: 10.3892/ol.2014.2159

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Ajji, Walder and Puri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.